To hear about similar clinical trials, please enter your email below
Trial Title:
Implementation of Actinic Keratosis Guideline Among General Practitioners.
NCT ID:
NCT05976048
Condition:
Actinic Keratoses
Conditions: Official terms:
Keratosis, Actinic
Keratosis
Conditions: Keywords:
actinic keratosis
general physician
5-fluorouracil cream
general practitioner
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Retrospective
Summary:
This study investigates 5-fluorouracil cream prescription trends by general practitioners
for the treatment of field changes of actinic keratosis over the years 2016-2021. The aim
is to analyse whether the publication of the multidisciplinary guideline on suspect skin
lesions for general practitioners in 2017 has made an impact in the prescribing behaviour
of general practitioners.
Detailed description:
Actinic keratosis is the most common epithelial precancerous lesion among the Caucasian
race. With an increase in prevalence worldwide due to an aging population and rise of
ultraviolet exposure actinic keratosis are among the most frequently encountered skin
lesions in clinical practice. Both dermatologists and general practitioners are
increasingly confronted with actinic keratosis, entailing to higher healthcare costs and
time burden.
There are many therapeutic modalities for the treatment of actinic keratosis, depending
on multiple factors such as distribution, characteristics, patient preference, side
effects, availability and costs. Treatment options can be divided into: lesion directed
therapy en field directed therapy. Both dermatologists and general practitioners can
treat actinic keratosis and 5-fluorouracil cream can also be prescribed by general
practitioners.
The objective of this study was to investigate 5-fluorouracil cream prescription trends
by general practitioner for the treatment of field changes of actinic keratosis over the
years 2016-2021.
Criteria for eligibility:
Study pop:
Data of patients with actinic keratosis in the general practitioners extracted from the
Research network family medicine (RNFM) Maastricht database between 2016 - 2021.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- age >18 years
- diagnosis actinic keratosis (clinical diagnosed or by biopsy)
Exclusion Criteria:
- cutaneous malignancy (suspicion)
- immunosuppressive co-medication.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Ellen Oyen
Address:
City:
Maastricht
Country:
Netherlands
Start date:
March 1, 2020
Completion date:
September 2024
Lead sponsor:
Agency:
Maastricht University Medical Center
Agency class:
Other
Source:
Maastricht University Medical Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05976048
